Recent Press Releases and Publications

Active Portfolio

Cessation Therapeutics

• (June 20, 2024): Cessation Therapeutics Announces Oral Presentation of Preliminary Findings from First-in-Human Study of Anti-Fentanyl Monoclonal Antibody, CSX-1004 - Pipelinereview
• (Oct 31, 2023): Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004 for Prevention of Fentanyl and Fentanyl Analog Overdose - BioSpace

Dialectic Therapeutics:

• (Nov 5, 2024): Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML | Blood | American Society of Hematology
• (April 5, 2022): Dialectic Therapeutics Announces DT2216 Has Received Fast Track Designation from the FDA for Adult Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma - BioSpace

Consolidated Restaurant Operations:

• (Sept 30, 2024): III Forks Announces State of the Art New Design for their Addison Flagship - cravedfw
• (Feb 12, 2024): The Last Word: III Forks President on Evolving His Steakhouse Brand with a 'Next-Level' Addison Location » Dallas Innovates

Exited Portfolio

AveXis

• (April 9, 2018): Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader

CerSci

• (August 25, 2020): ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio